MAR-GALANTAMINE ER 8 MG — DIN 02420821
GALANTAMINE (GALANTAMINE HYDROBROMIDE) : 8 MG · MARCAN PHARMACEUTICALS INC · CAPSULE (EXTENDED RELEASE) · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is MAR-GALANTAMINE ER?
MAR-GALANTAMINE ER 8 MG contains GALANTAMINE (GALANTAMINE HYDROBROMIDE) : 8 MG. It is listed in the Health Canada Drug Product Database under DIN 02420821, held by MARCAN PHARMACEUTICALS INC, supplied as CAPSULE (EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 10-May-2021. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Galantamine cost around the world?
Galantamine is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 4 | 24 | AUD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 15 | 20 | EUR███.██ |
| Greece | producer price (ex-factory) | 13 | 13 | EUR███.██ |
| South Africa | single exit price | 9 | 9 | ZAR███.██ |
| Saudi Arabia | public | 7 | 7 | SAR███.██ |
| Luxembourg | reimbursement | 5 | 5 | EUR███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
82 pack listings across 57 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Galantamine pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Galantamine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Galantamine, across 46 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JANSSEN INC | 9 | 3 | PAT-GALANTAMINE ER, REMINYL -(12MG), REMINYL -(4MG), REMINYL -(8MG), REMINYL ER | Sourceable in Canada |
| AURO PHARMA INC | 3 | 3 | AURO-GALANTAMINE ER | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 3 | 3 | MYLAN-GALANTAMINE ER | Sourceable in Canada |
| SANIS HEALTH INC | 3 | 3 | GALANTAMINE ER | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 6 | 0 | IPG-GALANTAMINE ER, MAR-GALANTAMINE ER | No marketed DIN |
| PHARMASCIENCE INC | 6 | 0 | PMS-GALANTAMINE, PMS-GALANTAMINE ER | No marketed DIN |
| APOTEX INC | 3 | 0 | APO-GALANTAMINE | No marketed DIN |
| PRO DOC LIMITEE | 3 | 0 | GALANTAMINE ER | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 3 | 0 | RATIO-GALANTAMINE | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 3 | 0 | SANDOZ GALANTAMINE ER | No marketed DIN |
| TEVA CANADA LIMITED | 3 | 0 | TEVA-GALANTAMINE ER | No marketed DIN |
| PENDOPHARM DIVISION OF PHARMASCIENCE INC | 1 | 0 | PENDO-GALANTAMINE ER | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 8 MG |
|---|---|
| Dosage form | CAPSULE (EXTENDED RELEASE) |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Galantamine |
|---|---|
| ATC code | N06DA04 |
| AHFS class | 12:04.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02420821 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2420821 |
| Brand name | MAR-GALANTAMINE ER |
| Generic / active ingredient | GALANTAMINE (GALANTAMINE HYDROBROMIDE) : 8 MG |
| Market authorization holder | MARCAN PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | N06DA04 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N06DA |
| Current status | CANCELLED POST MARKET |
| Status date | 10-May-2021 |
| Original market date | 2015-02-25 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 46 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-GALANTAMINE ER | 16 MG | CAPSULE (EXTENDED RELEASE) | AURO PHARMA INC | MARKETED | 02425165 |
| AURO-GALANTAMINE ER | 8 MG | CAPSULE (EXTENDED RELEASE) | AURO PHARMA INC | MARKETED | 02425157 |
| AURO-GALANTAMINE ER | 24 MG | CAPSULE (EXTENDED RELEASE) | AURO PHARMA INC | MARKETED | 02425173 |
| GALANTAMINE ER | 24 MG | CAPSULE (EXTENDED RELEASE) | SANIS HEALTH INC | MARKETED | 02443031 |
| GALANTAMINE ER | 8 MG | CAPSULE (EXTENDED RELEASE) | SANIS HEALTH INC | MARKETED | 02443015 |
| GALANTAMINE ER | 16 MG | CAPSULE (EXTENDED RELEASE) | SANIS HEALTH INC | MARKETED | 02443023 |
| MYLAN-GALANTAMINE ER | 24 MG | CAPSULE (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02339455 |
| MYLAN-GALANTAMINE ER | 16 MG | CAPSULE (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02339447 |
| MYLAN-GALANTAMINE ER | 8 MG | CAPSULE (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02339439 |
| PAT-GALANTAMINE ER | 24 MG | CAPSULE (EXTENDED RELEASE) | JANSSEN INC | MARKETED | 02316978 |
2 · Same class — other molecules in ATC N06DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Donepezil | ACCEL-DONEPEZIL · ACH-DONEPEZIL · ACT DONEPEZIL · ACT DONEPEZIL ODT · +30 more | 76 | 37 | Yes |
| Rivastigmine | ACT RIVASTIGMINE PATCH 10 · ACT RIVASTIGMINE PATCH 5 · APO-RIVASTIGMINE · AURO-RIVASTIGMINE · +25 more | 80 | 28 | Yes |
| Galantamine | APO-GALANTAMINE · AURO-GALANTAMINE ER · GALANTAMINE ER · IPG-GALANTAMINE ER · +13 more | 46 | 12 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N06D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N06DX | Memantine | 21 | 9 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MAR-GALANTAMINE ER called?
The same molecule, Galantamine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APO-Galantamine MR | Latin | Australia |
| Galantyl | Latin | Australia |
| Gamine XR | Latin | Australia |
| Reminyl | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.